Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Bortezomib clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Bortezomib as a study intervention. Browse Bortezomib recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced May 21, 2026, 2:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
289
Shown on this page
12
Local indexed summaries
289
Local recruiting
20
The trial list below is retrieved from the live ClinicalTrials.gov search API for Bortezomib. Results on this page are currently sorted by Recently updated.

Filter and sort this therapy

These controls apply only within Bortezomib. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 1–12 of 289 matching trials for Bortezomib.
Indexed local directory records.

Top conditions

Multiple Myeloma 91 Lymphoma 26 Unspecified Adult Solid Tumor, Protocol Specific 14 Multiple Myeloma and Plasma Cell Neoplasm 13 Recurrent Mantle Cell Lymphoma 12 Mantle Cell Lymphoma 10

Top sponsors

National Cancer Institute (NCI) 48 Janssen Research & Development, LLC 16 Memorial Sloan Kettering Cancer Center 10 Dana-Farber Cancer Institute 8 M.D. Anderson Cancer Center 8 Jonsson Comprehensive Cancer Center 7

Top locations

New York, New York 81 Boston, Massachusetts 78 Houston, Texas 51 Atlanta, Georgia 48 Seattle, Washington 44 Detroit, Michigan 42

Indexed official records

Open in full search
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

NCT07227311
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Belantamab mafodotin, Bortezomib, Carfilzomib, Dexamethasone, Pomalidomide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Torrance, California • Fort Myers, Florida • Macon, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 21, 2026, 1:22 AM EDT
Recruiting Phase 3 Interventional

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

NCT04566328
View directory record Official record
Conditions
Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
Interventions
Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Lenalidomide, Quality-of-Life Assessment
Drug · Biological · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
1,450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
642
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 457 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 21, 2026, 1:22 AM EDT
Recruiting Phase 3 Interventional

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06158841
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib, Carfilzomib, Dexamethasone, Elotuzumab, Etentamig, Pomalidomide, Selinexor
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
46
States / cities
Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 37 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 21, 2026, 1:22 AM EDT
Recruiting Phase 3 Interventional

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

NCT06152575
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib, Carfilzomib, Dexamethasone, Elotuzumab, Elranatamab, Pomalidomide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
97
States / cities
Mobile, Alabama • Goodyear, Arizona • Beverly Hills, California + 55 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 21, 2026, 1:22 AM EDT
Recruiting Phase 3 Interventional

A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT07222761
View directory record Official record
Conditions
Relapsed and/or Refractory Multiple Myeloma (RRMM)
Interventions
Bortezomib, Carfilzomib, Daratumumab, Dexamethasone, Linvoseltamab, Pomalidomide
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
915 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
2
States / cities
New York, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 18, 2026, 10:40 AM EDT
Recruiting Phase 3 Interventional

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

NCT06413498
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Anitocabtagene Autoleucel, Bortezomib, Carfilzomib, Cyclophosphamide, Daratumumab, Dexamethasone, Fludarabine, Pomalidomide
Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
50
States / cities
Gilbert, Arizona • Duarte, California • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced May 18, 2026, 10:40 AM EDT
Recruiting Phase 3 Interventional

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

NCT06022939
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bortezomib, Computed Tomography, Cyclophosphamide, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Echocardiography, Magnetic Resonance Imaging, Melphalan, Positron Emission Tomography, Stem Cell Isolation, Survey Administration
Procedure · Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
117
States / cities
Goodyear, Arizona • Tucson, Arizona • Duarte, California + 93 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced May 20, 2026, 8:43 AM EDT
Recruiting Phase 2 Interventional

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

NCT06390319
View directory record Official record
Conditions
Mixed Phenotype Acute Leukemia, T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma
Interventions
Bortezomib, Calaspargase pegol, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin, Dexamethasone, Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine), Mercaptopurine, Methotrexate, Nelarabine, Thioguanine, Venetoclax, Vincristine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
3
States / cities
San Diego, California • Tulsa, Oklahoma • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 21, 2026, 12:54 AM EDT
Recruiting Phase 3 Interventional

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

NCT07391657
View directory record Official record
Conditions
Relapsed Refractory Multiple Myeloma
Interventions
AZD0120, Bortezomib, Carfilzomib, Daratumumab, Dexamethasone, Pomalidomide
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
43
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced May 11, 2026, 4:38 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT05519085
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
Bortezomib, Dexamethasone, Pomalidomide, mezigdomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
56
States / cities
Los Alamitos, California • San Diego, California • West Hollywood, California + 50 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced May 17, 2026, 4:36 PM EDT
Recruiting Phase 1Phase 2 Interventional

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

NCT05848687
View directory record Official record
Conditions
Lymphoblastic Leukemia
Interventions
Blinatumomab, Bortezomib, Dexamethasone, Mercaptopurine, Methotrexate, Mitoxantrone, PEG asparaginase, Vorinostat, Ziftomenib
Drug
Lead sponsor
Tanja Andrea Gruber
Other
Eligibility
Up to 1 Year
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
17
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced May 20, 2026, 1:19 PM EDT
Recruiting Phase 2 Interventional

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

NCT06083922
View directory record Official record
Conditions
Monoclonal Gammopathy of Renal Significance, Multiple Myeloma
Interventions
Bortezomib, Cyclophosphamide, Daratumumab, Dexamethasone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced May 20, 2026, 12:22 AM EDT

About this Bortezomib clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Bortezomib as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Bortezomib.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Bortezomib.